Shu-Whei Tsai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shu-Whei Tsai has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Angela M. Early
Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
1 shared publication - Anne Ep Frosch
Affiliation Department of Medicine, Hennepin Healthcare Research Institute, University of Minnesota, Minneapolis, Minnesota, United States of America
1 shared publication - Bonnie Rayta
Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Brown University Warren Alpert Medical School, Providence, USA
1 shared publication - Charisse Flerida A. Pasaje
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
1 shared publication - Christian P. Nixon
Department of Pathology and Laboratory Medicine, Brown University
1 shared publication - Christina E. Nixon
Center for International Health Research, Rhode Island Hospital, Providence, RI 2
1 shared publication
Latest Publications
- Open Access
- 3 August 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (9)
A newly characterized malaria antigen on erythrocyte and merozoite surfaces induces parasite inhibitory antibodies
We previously identified a Plasmodium falciparum (Pf) protein of unknown function encoded by a single-copy gene, PF3D7_1134300, as a target of antibodies in plasma of Tanzanian children in a whole-proteome differential screen. Here we characterize this protein as a blood-stage antigen that localizes to the surface membranes of both parasitized erythrocytes and merozoites, hence its designation as Pf erythrocyte membrane and merozoite antigen 1 (PfEMMA1). Mouse anti-PfEMMA1 antisera and affinity-purified human anti-PfEMMA1 antibodies inhibited growth of P. falciparum strains by up to 68% in growth inhibition assays. Following challenge with uniformly fatal Plasmodium berghei (Pb) ANKA, up to 40% of mice immunized with recombinant PbEMMA1 self-cured, and median survival of lethally infected mice was up to 2.6-fold longer than controls (21 vs. 8 d, P = 0.005). Furthermore, high levels of naturally acquired human anti-PfEMMA1 antibodies were associated with a 46% decrease in parasitemia over 2.5 yr of follow-up of Tanzanian children. Together, these findings suggest that antibodies to PfEMMA1 mediate protection against malaria.
- 3 August 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (9)
Open AccessA newly characterized malaria antigen on erythrocyte and merozoite surfaces induces parasite inhibitory antibodies
We previously identified a Plasmodium falciparum (Pf) protein of unknown function encoded by a single-copy gene, PF3D7_1134300, as a target of antibodies in plasma of Tanzanian children in a whole-proteome differential screen. Here we characterize this protein as a blood-stage antigen that localizes to the surface membranes of both parasitized erythrocytes and merozoites, hence its designation as Pf erythrocyte membrane and merozoite antigen 1 (PfEMMA1). Mouse anti-PfEMMA1 antisera and affinity-purified human anti-PfEMMA1 antibodies inhibited growth of P. falciparum strains by up to 68% in growth inhibition assays. Following challenge with uniformly fatal Plasmodium berghei (Pb) ANKA, up to 40% of mice immunized with recombinant PbEMMA1 self-cured, and median survival of lethally infected mice was up to 2.6-fold longer than controls (21 vs. 8 d, P = 0.005). Furthermore, high levels of naturally acquired human anti-PfEMMA1 antibodies were associated with a 46% decrease in parasitemia over 2.5 yr of follow-up of Tanzanian children. Together, these findings suggest that antibodies to PfEMMA1 mediate protection against malaria.